Most lung cancer AI detects nodules. That is not the hard part. 🫁 The hard part is telling the radiologist which one is probably cancer, right now, not after three to six months of watchful waiting. This week, Eyonis and Canon Medical Systems' Olea Medical announced a strategic commercial agreement to expand U.S. access to eyonis LCS, according to Globe Newswire. Here is why this matters more than a typical distribution deal. 📌 The consensus is that detection AI is the finish line. Find the nodule. Flag the abnormality. Hand it to the radiologist. Done. My read: detection alone is actually where the dangerous ambiguity begins. 🔍 The evidence tells a different story. eyonis LCS is described as the first ...

$8.049 billion. That is what CMS is paying out in uncompensated care in FY 2027. 🏥 That number alone tells you how much structural weight hospitals are already carrying before a single new mandate kicks in. On July 31, 2026, CMS issued the FY 2027 Inpatient Prospective Payment System final rule. According to the National Law Review, it is scheduled for Federal Register publication on August 4, 2026. And it is packed with changes that every hospital finance, compliance, and strategy team needs to know right now. Save this post. Here is the breakdown. BEFORE vs. AFTER: THE RULE THAT CHANGED THE MOST Old rule: FDA breakthrough device designation or qualified infectious disease product (QIDP) status gave manufacturers an alternative ...

A simple stool test, offered every 2 years, cut colon cancer deaths in half. 🧬 That is not a headline from a clinical trial in a controlled setting. That is what happened in the real world, over 21 years, across 2.2 million people. According to Petra, the Jordan News Agency reporting on a study published August 5, 2026, the Basque Country's colorectal cancer screening program cut mortality among adults aged 50 to 69 by 50.1 percent. Mortality dropped from 39.7 to 19.8 deaths per 100,000 people. Without the program, researchers estimated mortality in that age group would have been 46.2 percent higher. The tool was not a colonoscopy. It was FIT, the Fecal Immunochemical Test, a non-invasive method that detects ...

Last week in healthcare funding moved serious money across 10 deals. 💰 From metastatic cancer to provider credentialing to youth mental health, the breadth was notable. Here is every deal I could verify: 🔹 AdvanCell, $315M, Series D. Advancing ADVC001, a Lead-212 PSMA-targeted radioligand therapy for metastatic prostate cancer toward Phase 3. The round was oversubscribed and upsized. 🔹 Beeline Medicines, $126.3M, Series A extension, bringing total Series A to $426.3M. Developing a portfolio of highly selective therapeutic candidates targeting the underlying causes of immune-mediated diseases including lupus and atopic dermatitis. 🔹 RQ Bio, $115M, Series A. Advancing RQB01, designed to deliver broad protection against influenza through a dual mechanism of action targeting conserved epitopes. Round described as oversubscribed. 🔹 ...

Last week in healthcare funding moved serious money across 10 deals. 💰 From metastatic cancer to provider credentialing to youth mental health, the breadth was notable. Here is every deal I could verify: - AdvanCell, $315M, Series D. Advancing ADVC001, a Lead-212 PSMA-targeted radioligand therapy for metastatic prostate cancer toward Phase 3. According to Diagnostics World News, the round was oversubscribed and upsized. - Beeline Medicines, $126.3M, Series A extension, bringing total Series A to $426.3M. Developing a portfolio of highly selective therapeutic candidates targeting the underlying causes of immune-mediated diseases including lupus and atopic dermatitis. Source: Diagnostics World News, July 29. - RQ Bio, $115M, Series A. Advancing RQB01, designed to deliver broad protection against influenza through a dual ...

Radiology is fighting four legislative battles at once. Here is what is actually at stake. 🏥 The Medicare fee schedule went up 3.26% in 2026. Sounds like progress. It is not. According to BC Advantage, that rate is still more than 7% lower today than it was 10 years ago. Meanwhile, four separate bills are moving through Congress right now, and most radiology operators I talk to know maybe one of them. Here is the full breakdown. 📋 The 4-Bill Radiology Legislation Framework (Summer 2026) 1. H.R. 8163, Provider Reimbursement Stability Act of 2026 This is the big one. It targets the structural math problem inside the Medicare Physician Fee Schedule. Key provisions: - Two-year lookback period to correct utilization ...

A scheduler in a busy imaging department is on her fourth call of the morning. 🔔 Two of her CT techs called out, there is no per diem pool left to tap, and the MRI suite opens in 40 minutes. This is not a bad week. This is Thursday. According to AHRA's Link publication, the 2025 ASRT Radiologic Sciences Workplace and Staffing Survey shows that overall pressure in medical imaging remains historically elevated across every major modality. The numbers are not directionally alarming. They are operationally disqualifying. 📊 THE 2025 VACANCY REALITY BY MODALITY Here is what the survey actually found: - CT: 19.4% vacancy rate, the highest in the 2025 survey - MRI: 17.4% - Cardiovascular interventional technology: 17.4% ...

37% less interpretation time. That is not a feature. That is a workflow reset. 🔬 DeepHealth just got FDA 510(k) clearance for an AI-powered breast ultrasound solution that does something most imaging AI still does not do: it handles detection, characterization, AND report generation in a single workflow. The consensus right now is that AI in radiology is an assist tool. It flags things. It surfaces findings. The radiologist still does the heavy lifting. My read is different. This clearance is a signal that the assist model is giving way to something more structural. Here is what the fetched press release actually says, verbatim: - Greater than 98% accuracy in localizing breast lesions - 8% improved sensitivity for breast cancer ...